Though there are a lot of similarities between the two peptides, there is no denying the fact that they also have vast differences. Besides having differences in the release of growth hormones and stimulation of pituitary glands, GHRP 2 is known to have better control in the release of prolactin and Cortisol. That’s not all; GHRP 2-based supplements are relatively cheaper as compared to other supplements that are available in the market, including the ones that are GHRP-6 based. There are a few individuals that opt for GHRP 6 due to the fact that it has lesser impact on prolactin and Cortisol; at least as compared to GHRP 2.
Peptides are short chain amino acid monomers linked by a peptide bond. The body utilizes these short amino acids chains to secrete/pulse growth hormone (GH) that is already stored in your body. This is a very attractive option for those who are not able to utilize synthetic human growth hormone (HGH) naturally. In fact, this could even be a safer alternative for those seeking to use growth hormone for recovery, anti-aging and fat-loss. There are a multitude of peptides on the market and new ones being created almost monthly. Therefore, for the sake of an overview, let me just touch upon the ones that are most commonly used. To begin, let me start by first breaking down the two most important peptide groups for bodybuilding.
by Bill Roberts – GHRP-6 is an injectable peptide in the category of growth hormone releasing peptides, or GHRP’s. The most common use of these peptides is to increase GH production. Other peptides in this category include GHRP-2, hexarelin, and ipamorelin. With regard to increasing GH, all of these work similarly, and there is no need or advantage to combining them. Instead, the one most suited for the particular case is chosen.
GHRP was first envisioned to be an analog of GHRH but, from comparison of the activity of GHRH and GHRPs between 1982 and1984, it was hypothesized to reflect the activity of a new hormone regulator of GH secretion, yet to be isolated and identified. Intravenous bolus GHRP releases more GH than GHRH in humans, but the reverse occurs in vitro. GHRPs are pleiotropic peptides with major effects on GH, nutrition, and metabolism, especially as an additional hormone in combination with GHRH as a new regulator of pulsatile GH secretion. The first indication of pleiotropism was an increase of food intake by GHRP. A major reason for the prolonged initial interest in the GHRPs has been its similar, yet different and complementary, action with GHRH on GH regulation and secretion.

Thanks to the assiduousness of talented researchers around the globe, our contemporary understanding of the pharmacology and probably also the physiological regulation of growth hormone secretion, came about after the important discovery that GHRP increased pulsatile GH secretion in not only children, but also within normal younger and older men and women. Even though GHRP alone substantially releases GH from the pituitary in vitro without the addition of GHRH, this rhythmic endogenous secretion does require some GHRH.

GHRH/GHRP-6 was the first of a family of synthetic peptides that enhance the release of the GH by the pituitary gland in a dose-dependent manner. Since its discovery, it has been used as a benchmark and starting point for many of the research aims to obtain new drugs, but none of its implications are more engaging than the treating of the obesity epidemic.
This is the most popular variant of IGF-1 that buyers will find on the market today. IGF-1 LR3 comprises 83 amino acids. That means it adds extra 13 amino acids to the sequence of the standard insulin-like growth factor-1. The polypeptide boasts qualities that make it much more powerful than normal IGF-1. It boasts a longer half life of up to 30 hours, compared to the latter’s 15 hours. In addition to bodybuilding, IGF-1 LR3 helps with fat burning, quicker recovery and slowing aging.

Morphological evidences representative of the GHRP-6 effect in a porcine model of myocardial infarction. Effect of the GHRP-6 on AMI size and severity. (A, B) Macroscopic and histological images of AMI damage in animals treated with placebo. (C, D) Macroscopic and histological images representative of the GHRP-6 cardioprotective effect. Histological fragments were in every case collected from apparently normal zones, adjacent to the AMI necrotic core. Rats treated with GHRP-6 exhibited mostly preserved or marginally damaged (sarcoplasmic edema) myofibrils. No myofibrolysis was observed, although a number of ghost nuclei appeared. (H/E, ×20 magnification).
Without going into great detail, think of GHRP’s as targeting a pulse when you want it; meaning, once you take it, you get a burst of GH. On the other hand, with GHRH’s you really have to time when your body will have its own pulse to get the most out of administering them. In simple terms, if you use GHRH's at the wrong time, the results are minimal.
Growth Hormone Releasing Peptide 6 ( GHRP-6) is a peptide which substantially activates the pituitary gland into releasing high levels of growth hormone for a few hours. The increase in growth hormone comes from your own body, not synthetic growth hormones which can suppress your natural production. GHRP 6 is a first generation GHRP and has a few side effects which could be annoying.
Finally, the ghrelin chemical isolation and identification was accomplished surprisingly from the stomach, which is the major site but not the only site. Ghrelin was isolated and identified.4 A primary action of GHRPs continues to concern GH secretion and regulation, but increasingly this has included direct and indirect effects on nutrition and metabolism, as well as a variety of other actions which may be pharmacological and/or physiological.
hi i have just bought the same as what you mentioned, can you give me a bit of info from your experience, like how quickly results will be seen? your experience on how much fat loss you achieved and any muscle you gained? i have a solid weight and food plan and im smashing out plenty of cardio too, and need to lose another 10 lb. all the best kayne
As a result, a general guideline for the purpose of achieving performance and physique enhancement is that of 100mcg administered three times per day. Each injection should be spaced evenly apart in order to achieve substantial HGH levels throughout the day due to the short half-life of GHRP-6 as well as the pulsatile manner of the HGH release that it causes. For greater results that would include more pronounced muscle gain and fat loss, more frequent injections would be required above the three times per day protocol. More details concerning the specific administration timing will be described shortly.
TO-2 hamster model of DCM was characterized by progressive LV dilation, LV wall thinning, LV systolic dysfunction, and reduced life span; both GHRP-2 and GHRP-6 ameliorated all the dysfunctional ventricular parameters and reduced the progression of the DCM.34 We also examined the potential impact of GHRP-6 in a rat model of DCM/heart failure induced by doxorubicin (DX). The concurrent administration of GHRP-6 was undertaken with the purpose to study the potential prophylactic impact before the cardiac function demise. As part of the prolonged treatment with DX, the concurrent administration of GHRP-6 completely prevented failure of cardiac function, which was evaluated as the percentage of ejection fraction by echocardiography (Figure 2, prevention). This effect significantly increased the survival of animals. Similar results were obtained in the therapeutic administration schedule, with functional recovery of cardiac muscle to physiological levels (Figure 2, regression), also attenuating systemic damages and, consequently, decreasing the mortality rates of rats. In the experimental model of DX-induced cardiac and systemic damage, GHRP-6 additionally attenuated various extracardiac damages observed in the renal tubular and bronchoalveolar epithelial structures as in the hepatic parenchyma.35
GHRP was first envisioned to be an analog of GHRH but, from comparison of the activity of GHRH and GHRPs between 1982 and1984, it was hypothesized to reflect the activity of a new hormone regulator of GH secretion, yet to be isolated and identified. Intravenous bolus GHRP releases more GH than GHRH in humans, but the reverse occurs in vitro. GHRPs are pleiotropic peptides with major effects on GH, nutrition, and metabolism, especially as an additional hormone in combination with GHRH as a new regulator of pulsatile GH secretion. The first indication of pleiotropism was an increase of food intake by GHRP. A major reason for the prolonged initial interest in the GHRPs has been its similar, yet different and complementary, action with GHRH on GH regulation and secretion.
GHRPs bind to two different receptors (GHS-R1a and CD36), which redundantly or independently exert relevant biological effects. GHRPs’ binding to CD36 activates prosurvival pathways such as PI-3K/AKT1, thus reducing cellular death. Furthermore, GHRPs decrease reactive oxygen species (ROS) spillover, enhance the antioxidant defenses, and reduce inflammation. These cytoprotective abilities have been revealed in cardiac, neuronal, gastrointestinal, and hepatic cells, representing a comprehensive spectrum of protection of parenchymal organs. Antifibrotic effects have been attributed to some of the GHRPs by counteracting fibrogenic cytokines. In addition, GHRP family members have shown a potent myotropic effect by promoting anabolia and inhibiting catabolia. Finally, GHRPs exhibit a broad safety profile in preclinical and clinical settings. Despite these fragmented lines incite to envision multiple pharmacological uses for GHRPs, especially as a myocardial reperfusion damage-attenuating candidate, this family of “drugable” peptides awaits for a definitive clinical niche.

The potent biologic effects of GHRPs and the identification of the GHS-R suggested the existence of a natural ligand for the receptor that is involved in the physiologic regulation of GH secretion. The acylated peptide ghrelin, produced and secreted into the circulation from the stomach, is this ligand (Fig. 7-22). The effects of ghrelin on GH secretion in humans are identical to or more potent than those of the non-natural GHRPs (see Fig. 7-20). In addition, ghrelin acutely increases circulating PRL, ACTH, cortisol, and aldosterone levels. There is debate con­cerning the extent and localization of ghrelin expression in the brain that must be resolved before the implications of gastric-derived ghrelin in the regulation of pituitary hormone secretion are fully understood. Furthermore, post-translational processing of pro-ghrelin gives rise to a second neuropeptide, obestatin, which may also have functional roles in activity of the GH/IGF-1 axis and metabolism. A proposed role for pro-ghrelin peptides in appetite and the regulation of food intake is discussed in Chapter 35.
Figure 2: GHRP-6-mediated response to inflammation. Images are representative of (a) wounds topically treated with vehicle (1% CMC); (b) wounds topically treated with GHRP-6. GHRP-6 treatment reduced the inflammatory infiltration of mononuclear basophilic round cells. In contrast, CMC-treated wounds exhibit a physiologically normal infiltration, which matches the biological stage of the wound. 5 μm section, H/E, 20x magnification.
The original GRF (1-29) has a half-life of about 30 minutes. Half-life means the time within which half of the hormone administered will be destroyed within the body. This short half-life is due to the fact that the compound is highly unstable and breaks down soon. To increase its stability and to make it last longer, it was modified by adding 4 amino acids in its structure. This gave it the name Modified GRF (1-29) or Mod GRF 1-29. It was originally invented by DatBtrue. The portion of the molecule that actually stimulates the growth hormone secretion is found in the chain of 29 amino acids, so it is named GRF (1-29). This chemical also produces slow-wave sleep.

During studies of the opioidal control of GH secretion several analogs of met-enkephalin were found to be potent GH secretagogs. Among them were GH-releasing peptide-6 (GHRP-6), and hexarelin (His-D2MeTRP-Ala-Trp-DPhe-Lys-NH2) (Laron, 1995). They act via a receptor unrelated to that of GHRH (Howard et al., 1996). The potent biologic action of the GHRPs and the identification of a specific receptor suggested the existence of a natural ligand.
The consumption of such altered compounds may have severe consequences on the user's body and it is critical that they avoid such scenarios. The authorities need to grab the perpetrators responsible for the peddling of these illegal drugs in the market and regulate the black market. Given the many advantages this drug has for the human body and its potential as the all-round supplement, the authorities need to encourage the research and development agencies working on this drugs development. The emphasis should be on making it safer, more side-effect friendly and more compatible to mixing with other anabolic steroids.
I'm new to the forum and there is some great information here that I need to do more reading on. I've been taking Ipam and ModGrf 1-29 for at least 2yrs now. The first thing I noticed is that I have good quality sleep. I have difficulty sleeping and staying asleep. I take these peps 20min before I go to bed and get a good deep sleep for at least most of the night. I take them before doing my morning cardio, after my workout (afternoon) and before I go to bed. I've read if you take it before your morning cardio it releases more FFA to burn during your session. After the workout to aid in recovery. Before bed to aid in a deeper sleep. It is important when you take them. Dont eat before morning carbs/sugary drinks...3hrs should have passed before taking another shot and do not eat before 15-20min after taking the peps. The reason (I've read) to wait these times is to take them while your insulin levels are low. High Insulin levels will minimize the pulsation of the GH. The phrase I've read is to try to keep "insulin quiet" to maximize the pulse of GH. Ipam can work by itself but if taken with ModGrf 1-29 it will magnify the GH Pulse. ModGrf is useless by itself. I've read that there is a saturation dose, so more is not better. 200mcg for each should do the job. Since synthetic GH shuts down natural production, these peps stimulate the pituitary to pulse more natural GH. To get the maximum effect of syn GH, you would also take the shot at the same time discussed above. Once again, this is what I've read and the protocol that I've followed. The results arent like AAS (nothing is!) but it is a good way to feel better since I cant take TRT. (trying to have kids) I also travel with the peps bc I value the sleep that I get from it.

The prescription form of IGF-1 most often injected is “mecasermin”, which goes by the trade name Increlex. Manufactured using recombinant DNA technology, mecasermin is clinically used to treat IGF-1 deficiency and stunted growth. It is also prescribed to patients who have developed antibody resistance to normal growth hormone therapy. Increlex is actually identical to natural IGF-1, meaning that it has the identical 70 amino acid sequence of IGF-1 that the body produces. In other words, it’s not some kind of growth hormone “precursor”. It’s just straight up IGF-1.
Hexarelin via CD36 occupation increases the expression of multiple genes involved in fatty acid mobilization in adipocytes toward the mitochondrial oxidative phosphorylation, and many of these upregulated genes are known targets of PPARγ. Consistent with this, electron microscopy of hexarelin-treated adipocytes reflects highly organized cristae formation that spans the entire width of mitochondria, with a concomitant cytochrome c oxidase activity enhancement. Although this signaling and activation cascade has not been described for myocardial cells so far, the potential existence of these phosphorylative and mitochondriogenic mechanisms in the heart, and its potential amplification by GHRP ligands, may eventually contribute to myocardial salvage during critical ischemia periods.47 In a more recent study based on a myocardial infarction model, and addressed to examine whether hexarelin treatment can compensate for ghrelin deficiency in ghrelin-knockout mice, the mortality within two weeks was significantly lower in the hexarelin (6.7%) and ghrelin groups (14.3%) than in the vehicle group (50%). Furthermore, hexarelin was more effective than ghrelin as judged by the ejection fraction and other LV-dependent physiological constants as dP/dt max and dP/dt min, which is a measure of LV global contractility.48
Biokey Research OSTA-MAX 25 BRAND: BIOKEY RESEARCH  OSTARINE (MK-2866) Purity : 99% Molecular Formula : C19H14F3N3O3 Molecular Weight: 389.33 CAS#: 841205-47-8 Description: MK-2866 Ostarine 30ml @ 25mg per ml Recommended dosage: 0.5-1ml daily DESCRIPTION OSTA-MAX 25 by BioKey Research contains 25mg/ml of MK-2866. This compound is often compared it its illegal anabolic counterparts due its ability to reduce body fat while increasing lean muscle mass. OSTA-MAX 25…
Author Contributions: Conceived and designed the experiments: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, GGN. Analyzed the data: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB. Wrote the first draft of the manuscript: JBA. Contributed to the writing of the manuscript: JBA, AGO, YMM. Agree with manuscript results and conclusions: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, QB, GGN. Jointly developed the structure and arguments for the paper: JBA, AGO, GGN. Made critical revisions and approved final version: QB, GGN. All authors reviewed and approved of the final manuscript.
Of particular note is the variable chemistry of GHRPs, which consist of three major chemical classes including peptides, partial peptides, and nonpeptides, all of which appear to act via the same receptor and cellular mechanisms. Generally, most GHRPs are active by all routes of administration, specifically intravenously (IV), subcutaneously (SC), orally, intranasally, and intracerebroventricularly (IVC), which supports their possible broad future clinical utility. From evolutionary studies starting with the zebrafish, the natural receptor and hormone have been present for hundreds of years, underscoring the fundamental evolutionary and functional importance of the ghrelin system. GHRPs were well established to act directly on both the hypothalamus and pituitary several years before the GHS receptor assay.23
Thymosin alpha-1 (T α 1) is a peptide, or small protein, consisting of 28 amino acids. T α 1 is produced naturally by the thymus gland. The thymus is located behind the sternum and between the lungs, and is where immune cells known as T cells mature and are released, prompted to do so by the T α 1 peptide. T cell production and action within the body is vital to adaptive immunity—the mode by which immune cells are able to recognize and eradicate foreign invaders.
The delegates' reasons for the final decision to exempt from the proposed Appendix C entries, teeth whitening preparations containing more than18 per cent of carbamide peroxide and more than 6 per cent of hydrogen peroxide manufactured for and supplied solely by registered dental practitioners as part of their dental practice, comprise of the following.
So… now we get down to the individual peptides themselves. I will not go into length with a profile for each one, but instead I will provide two charts that should help in understanding which peptides are GHRH’s and which ones are GHRP’s. Of course, IGF and MGF have their own respective spots but do not have the synergy when combined like GHRP and GHRH.
There is evidence of involvement of organised crime in supply of the substances. The substances are offered for sale via the internet. Many of the substances are promoted as safe alternatives to traditional performance enhancing substances such as the anabolic steroids. Suppliers are making unproven assertions about the efficacy and safety of the substances.
In another study, it was concluded that the major target of the GHRP-6 in vivo (both laboratory animals and humans) is the hypothalamus. From the observation, it was concluded that the GH release induced by the central GHRP-6 injections in guinea pigs was inhibited by the central action of somatostatin. Furthermore, an inhibition by somatostatin with the activated GRF neurons, induced by GHRP-6, was observed via receptors known to be located on or near the GRF themselves. This particular experiment further indicated that GHRP-6 is effectively stimulating GH release from somatotrophs through different receptors, the mechanisms of which are not yet known (Chan et al. 1989).

These studies on human subjects were paralleled by contemporary experimental progresses in basic science, which demonstrated that hexarelin enhanced H9c2 cardiomyocyte proliferation in a dose-dependent manner. Since these were in vitro experiments, they completely excluded a potential intervention of the GH axis and clearly indicated a direct GHRP binding to cardiac cells membranes.32 Weekers et al33 demonstrated that 14 days of pretreatment with GHRP-2, but not GH, selectively protected against the postischemic diastolic dysfunction and myocardial stunning of excised hearts submitted to ischemia/reperfusion in isolated, perfused rabbit hearts.
CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
There is no “one right way”, to use Ipamorelin. For example, if you are using 500 to 1000 mcg doses daily, twice a day, your cycle might run for an 8 week period. If on the other hand, you are an athlete training for a competition, you might be on 3 injections per day, at 300-500 mcg, and will stay on for a 12 week period. For new users, you might find a 300 mcg injection is too high, and you will cut back to 200 mcg until your body gets used to it, for an 8-week cycle.
IGF-1 causes hyperplasia and muscle and strength increase, looove IGF-1 (insulin-like growth factor). GHRP-6 causes your pituitary gland the secret growth hormones so you get a 'pulse' after each shot. The more shots, the more pulses you get which is why I split it up to 3 times a day. You feel amazing post-shot and also hungry as fuuu within 20 minutes, like a bottomless stomach. Also helps with fat-loss.

The Half Life of GHRP 2 is pretty short. GHRP 2 helps improve the levels of calcium in the body and this can in turn facilitate the secretion of other growth hormones. GHRP 2 is believed to be more potent in its operation as compared to other peptide forms, including GHRP 6. GHRP 2 has the ability to stimulate secretion of other growth hormones and increase food consumption. When you start taking in GHRP 2 at regular intervals the level of growth hormones being released in your body increases considerably. GHRP 2 is known to have better control in the release of prolactin and Cortisol. 

TGA evaluator concluded that the consistent absence of any clinically meaningful effects on blood pressure (BP) or heart rate (HR) in the applicant's bioavailability studies, and the absence of any ADR reports of BP, HR or other cardiovascular problems, indicate that "there is no valid reason for concern and no need to take any regulatory against the combination products currently in the ARTG and available in the Australian market", i.e. no demonstrated safety risk, and no evidence provided of efficacy of paracetamol 1000 mg / phenylephrine HCl 5 mg adult dose.

"a number of weeks in on a S4 research using 5 day on 2day off . Results o far include muscle hardening very noticeable on resting biceps. Strength has increased by 20% with it seems like no end to sets with recovery and endurance unreal. Just when you thought you was done , rest and here we go again. Not a great deal of muscle soreness days later which makes me increase my weights next session. There was a few sides with a elite sensitivity to light to dark and hunger was weird. Not needing to eat but when eating it was awesome. Loved what I eating even more as tho I had been very hungry. Customer service and delivery from you guys was second to none. Ordered on a Sunday received on Tuesday morning. Well packed. Love the ease of use on your web site. Great quality products and service. I can't wait to purchase more from you guys." Arnie

In studies of the opioid control of GH secretion, several peptide analogues of met-enkephalin were found to be potent GH secretagogues. These include the GH-releasing peptide GHRP-6 (Fig. 7-21), hexarelin (His-d2MeTrp-Ala-Trp-dPhe-Lys-NH2), and other more potent analogues including cyclic peptides and modified pentapeptides. Subsequently, a series of nonpeptidyl GHRP mimetics were synthesized with greater oral bioavailability, including the spiropiperidine MK-0677 and the shorter acting benzylpiperidine L-163,540 (see Fig. 7-21). Common to all these compounds, and the basis of their differentiation from GHRH analogues in pharmacologic activity screens, is their activation of phospholipase C and inositol 1,4,5-trisphosphate. This property was exploited in a cloning strategy that led to the identification of a novel GPCR GHS-R that is highly selective for the GH secretagogue class of ligands. The GHS-R is unrelated to the GHRH receptor and is highly expressed in the anterior pituitary gland and multiple brain areas, including the medial basal hypothalamus, the hippocampus, and the mesencephalic nuclei that are centers of dopamine and serotonin production.
Researchers around the globe suggest that the effectiveness of growth hormones depends a lot on the physical condition of the subject being administered with the drug. If the subject is obese, then there may not be the desired level of hormone secretion. Obesity seems to affect the effectiveness of GHRP-6 but if the subjects are not obese, the effects of this drug is likely to be the same for all gender or age groups, subject to the administered dosage.
MuscleSport AlphaSRM Builds muscle and burns fat simultaneously* 4 research validated testosterone enhancers* 5 effective thermogenic compounds* Increases metabolic rate* Inhibits aromatase* Nitrosigine® for muscle-engorging pumps* Building or retaining muscle while simultaneously losing fat has been described as a near impossible task. This “body recompositioning” often requires a calorie deficit or surplus that may deprive your body of key muscle…

Prior to the 2008 Beijing Olympics, concerns were raised regarding cardarine which was creating significant and “remarkable” performance and endurance advantages without being regulated, so some athletes were potentially getting unfair advantages. While tests for cardarine weren’t developed in time for the Olympic Games, the following year PPARδ agonists (of which cardarine is included) were added to the WADA prohibited list.
ADV Research ADV-17 Post Cycle Therapy PRODUCT STRENGTH (CONCENTRATION): 30MG/ML KEY BENEFITS Raises testosterone levels Lowers estrogen levels Raises luteinizing hormone (LH) levels Lowers cortisol levels Enhances recovery speed Promotes vascularity (hardening and drying out) Increases libido Inhibits gynecomastia (male breast enlargement) Promotes fat loss Not liver toxic GENDER SUITABILITY ADV-17 is suitable for use by males. Females should not…
Results in Fig. 1.8 of normal young men (left panel) and women (right panel) demonstrate that iv bolus combined GHRP-2 and GHRH at the respective doses of 1 μg/kg GHRH and a subthreshold GH-releasing dose of 0.03 μg/kg GHRP-2 released GH synergistically (Bowers, 1998). From these studies, GHRP is envisioned to act on the hypothalamus to release an unknown factor (U factor) rather than endogenous GHRH which subsequently acts concomitantly with GHRH on the pituitary somatotroph to release GH synergistically. In this study, the important specific finding is that GHRP-2 augments GHRH release even when GHRH is present in excess amounts, and the concomitant GHRP-2 dose of 0.03 μg/kg is a subthreshold GH-releasing amount. Thus, GHRP + GHRH is not releasing GH in this study by augmenting endogenous GHRH release and, furthermore, GHRP+GHRH release in vitro is additive and not synergistic. In addition, from other high-dosage GHRP-2 data, that is, 10 μg/kg sc (not shown), we have postulated that at high doses GHRPs do act on the hypothalamus to release endogenous GHRH because high-dose GHRP-2 (10 μg/kg sc) releases the same large amount of GH released by combined GHRH + GHRP-2 at 1 + 1 μg/kg iv (Bowers, 1998a,b).

Another major difference between GHRP 2 and GHRP 6 is that the former is a bit stronger and releases a lot more Growth Hormone as compared to GHRP 6. Therefore, if increasing Growth Hormone in you is of prime importance then consider choosing GHRP 2 makes a lot of sense. But the importance of the latter in stimulating appetite cannot be ignored altogether. Though GHRP 2 can also be used for the same purpose, it is certainly not in the same level as that of GHRP 6.